Purkiss Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.22M Hold
36,627
0.98% 27
2025
Q4
$1.98M Hold
36,627
0.93% 24
2025
Q3
$1.65M Hold
36,627
0.79% 29
2025
Q2
$1.7M Sell
36,627
-1,182
-3% -$58K 0.94% 22
2025
Q1
$2.31M Buy
37,809
+83
+0.2% +$4.84K 1.74% 7
2024
Q4
$2.13M Buy
+37,726
New +$2.11M 1.84% 8

Other funds holding BMY

Purkiss Capital Advisors's BMY Position: Q1 2026 in Review

Purkiss Capital Advisors held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 36,627 shares worth $2.22M. The position accounts for 0.98% of the portfolio, ranked #27.

Purkiss Capital Advisors first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.31M in Q1 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Purkiss Capital Advisors held 36,627 shares of Bristol-Myers Squibb worth $2.22M as of Q1 2026.
  • Purkiss Capital Advisors left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.98% of Purkiss Capital Advisors's portfolio in Q1 2026, its #27 holding.
  • Purkiss Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • Purkiss Capital Advisors's Bristol-Myers Squibb position peaked at $2.31M in Q1 2025.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Purkiss Capital Advisors's 13F filing for Q1 2026, filed 4 May 2026.